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There is a need for diverse molecular libraries for phenotype-selective and high-throughput screening. To make marine
natural products (MNPs) more amenable to newer screening paradigms and shorten discovery time lines, we have
created an MNP library characterized online using MS. To test the potential of the library, we screened a subset of the
library in a phenotype-selective screen to identify compounds that inhibited the growth of BRCA2-deﬁcient cells.
Historically, natural products and their derivatives have been a
major source of pharmaceutical leads and therapeutic agents.
1 In
particular, marine natural products (MNPs) have demonstrated
exceptional potency and potential as anticancer therapeutics.
2,3
Natural products have evolved over millions of years to elicit
precisely tuned biological effects. As a result, many natural products
occupy chemical space that is different from and complementary
to that in synthetic libraries, making natural product libraries
attractive for drug discovery.
4,5
Large screening campaigns have demonstrated the need for high-
quality molecular libraries in order to promote drug discovery.
6
However, crude natural product extracts are not well suited for high-
throughput screening especially in single protein assays.
5,7 In the
pharmaceutical industry, difﬁculties encountered with natural
products in high-throughput screening (HTS) campaigns have
resulted in a decreased emphasis in natural products drug discovery.
5
In an attempt to fully exploit the chemical diversity present in
sponges and ascidians, we have developed methodology to produce
high-purity natural product libraries for high-throughput screening
and phenotype-selective screens.
A major goal for developing libraries was to address the issues
that have made natural products less amenable to the high-
throughput paradigm. These include the complexity of crude
extracts, dereplication time, and a lag in prioritization of lead
compounds compared to synthetic libraries. However, advances in
approaches to natural products drug discovery incorporating new
technologies have helped to overcome these difﬁculties.
8,9 The
pioneering work by researchers at Sequoia Sciences set the stage
for combining MS analyses with the generation of large natural
product libraries.
10,11 More recently, the potential for marine natural
product libraries to accelerate drug discovery was demonstrated
using a yeast halo assay.
12
We have developed a two-dimensional chromatographic strategy
that includes an automated HPLC-MS fractionation protocol to
generate natural product libraries that are sufﬁciently pure for HTS
and characterized by accurate mass during production to expedite
dereplication of known compounds and identiﬁcation of novel
chemotypes. The ﬁnal fractionation is directed into 96-well format
with each well being mapped to an MS chromatogram. Through
the use of monolithic HPLC column technology, we can obtain
sufﬁcient material in each well from a single HPLC injection not
only for performing multiple screens but also for NMR studies.
Using this approach to generate screening libraries, we have
performed selective screens, conﬁrmed the structures of active leads,
and identiﬁed a likely mechanism of action directly from the library.
Effectively, this methodology has the potential to eliminate bioas-
say-guided fractionation.
We utilized HP20SS for initial separation followed by C18 RP-
HPLC. This two-dimensional approach using orthogonal techniques
afforded essentially unit resolution. Since the marine invertebrate
extracts contained high amounts of inorganic salts, we needed to
effectively desalt the extract prior to any LCMS analysis to avoid
suppressing ionization. This was effectively performed by drying
extracts onto HP20SS and performing solid-phase extraction (SPE).
Washing the extract-loaded resin with 100% H2O efﬁciently
removed salts, while the organics were separated using a four-step
elution (see Experimental Section). The eluates were subsequently
plated in 96-well plates for use in an autosampler, dried in a
centrifugal evaporator, and resolubilized in DMSO prior to HPLC.
The efﬂuent from the HPLC was split after a photodiode array
detector with the majority going to a fraction collector and a small
amount to a Q-tof Micro equipped with lockspray to enable accurate
mass measurements. Fractions were obtained using one-minute time
slices and were mapped on both the mass and PDA chromatograms
using FractionLynx to correlate the contents of each well in the
collection plate.
One difﬁculty was to effectively separate a wide variety of natural
product mixtures in a slug of DMSO while processing enough
material for screening and follow-up NMR studies. Since our
fraction collection was limited to <2 mL volumes due to the
capacity of a deep-well collection plate, we had to achieve
separation without resorting to traditional semipreparative chro-
matography. This problem was solved by utilizing a Phenomenex
3m m× 100 mm Onyx C18 monolithic HPLC column. Although
this column is much smaller than a traditional semipreparative
column, we were able to obtain efﬁcient separation of most HP20SS
fractions on 2 mg dissolved in 200 µL of DMSO. Monolithic
columns have demonstrated increased efﬁciency and higher capacity
with decreased back pressure when compared to traditional packed
HPLC columns.
13,14 After HPLC, the contents of the collection
plate were split to make two identical daughter plates, one for
screening and one for a material archive. We have now processed
768 HP20SS fractions to generate a 15 360-membered marine
natural products library for HTS and phenotype-selective screens.
To demonstrate the potential of the library for drug discovery,
the library was screened in a paired cell line phenotype assay to
identify leads that demonstrated selectivity toward BRCA2-deﬁcient
tumor cells. Optimal cancer chemotherapy would allow the selective
elimination of tumor cells over normal cells by exploiting the
molecular differences between tumor cells and normal cells. The
genetic susceptibility to breast cancer caused by mutations in
BRCA1 and BRCA2 provides an opportunity to identify small
molecules that selectively inhibit the growth of BRCA2-deﬁcient
cells. Both BRCA1 and BRCA2 proteins are important for the repair
of double-strand DNA breaks. As a result, BRCA2-deﬁcient cells
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and are hypersensitive to ionizing radiation and DNA cross-linking
agents.
15,16
In order to identify novel small-molecule inhibitors with speciﬁc-
ity for cells compromised in BRCA2 function, we designed a
phenotypic screen. This approach utilized a matched set of hamster
cell lines, including one that was mutated at the BRCA2 locus,
V-C8, and therefore deﬁcient for BRCA2. The other line, BAC29,
was wild-type for BRCA2; the BRCA2 protein was restored by
complementation with a mouse BRCA2 gene.
15
Initially, a portion of the library (5000 wells) was screened for
toxicity in V-C8 cells. All samples showing >75% reduction in
cell viability were subsequently screened in V-C8 and isogenic
BAC29 cells. In order to validate the assay performance and the
biological response of the BRCA2-deﬁcient and -proﬁcient cell
lines, they were treated with the DNA alkylating agent mitomycin
C. The viability of cells was measured using the WST1 reagent
three days after compound exposure. Mitomycin C was cytotoxic
in both cell lines, exhibiting more than 200-fold selectivity for
BRCA2-deﬁcient cells (see Table 1). Of the 252 cytotoxic fractions
from the MNP library, only ﬁve showed 3- to 8-fold selectivity for
V-C8 cells over BAC29 cells (see Table 1). Four of the ﬁve were
from the same sponge, Plakortis quasiamphiaster Dı ´az and van
Soest, 1994 (family Plakinidae), and the remaining sample was from
a Crella spinulata (Hentschel, 1911) (family Crellidae).
Once the activity of the ﬁve prioritized wells was conﬁrmed,
we extracted the MS data from the chromatogram that corresponded
to each well. On the basis of accurate mass measurements and
taxonomy of the P. quasiamphiaster, we were able to quickly
propose the presence of plakinidines A, B, and C (1-3).
17–19 A
literature search on C. spinulata suggested compounds such as
crellastatin A,
20 which was reported to be a colorless compound
and a potent inhibitor of cell growth. However, this class was not
supported by the MS data, and the active fraction was reddish-
purple. In order to conﬁrm the structures of the compounds, the
contents of the prioritized wells from the archive plate were
transferred directly to an NMR tube for anlayses. On the basis of
equal distribution, we anticipated that each well in the archive plate
would contain approximately 50 µg and NMR analyses might be
difﬁcult. However, we were able to obtain data using a 600 MHz
cryoprobe (see Figure 1, Supporting Information). We were able
to obtain gCOSY and gHSQC spectra on each sample and conﬁrm
the contents of each well.
Interestingly, the NMR data for the active sample from C.
spinulata indicated it was a mixture of plakinidines, which have
not been previously reported from this sponge. For the C. spinulata,
a bright red sponge, only one colored metabolite has been reported,
benzothiocrellidone, a bright yellow solid.
21 We believe that the
selective activity of the plakinidines in C. spinulata would have
been masked in a crude extract by the cytotoxic crellastatins. This
example clearly illustrates the power of screening puriﬁed MNP
libraries in phenotype-selective assays.
On the basis of the pyridoacridine structure and selective
cytotoxicity in BRCA2-deﬁcient cells, we hypothesized that the
plakinidines were DNA intercalators. The preferential toxicity of
these compounds could be explained by interaction of these
compounds with DNA and the inability of the BRCA2-deﬁcient
cells to efﬁciently repair the resulting DNA damage that ensues
during transcription or replication. To test this hypothesis, samples
were taken directly from the screening plate and incubated at a
concentration of 33 µM with 250 ng of pRYG negatively super-
coiled plasmid DNA (Topogen, Port Orange, FL) for 21 h. Samples
were then subjected to electrophoresis on 1% agarose gels in the
absence of ethidium bromide. Following electrophoresis, the gels
were stained with 0.5 µgm L -1 ethidium bromide. Intercalation
between bases in DNA reduces negative supercoiling, which was
readily monitored by alteration in electrophoretic mobility of
plasmid DNA in agarose gels. The reduced electrophoretic mobility
in the presence of samples from all ﬁve wells indicated a reduction
of the negative superhelicity of the plasmid DNA (see Figure 1).
We have demonstrated that high-quality MNP libraries of
sufﬁcient purity for HTS and phenotype-selective screening can
be generated. In most cases, we observed three compounds or less
per well. For the example presented here, our method has eliminated
bioassay-guided fractionation and allowed rapid identiﬁcation of
lead structures while providing enough sample for multiple screens.
Additionally, we have been able to identify a mechanism of action
for the cytotoxicity of the plakinidines without the need to re-extract
Table 1. Differential Cytotoxicity
IC50, µM
VC-8 BAC29 SI
a compound(s)
MPI-0454126 0.30 0.99 3.29 plakinidines A (1) ,B( 2), and C (3)
b
MPI-0454127 0.04 0.16 5.47 plakinidines A (1)a n dC( 3)( ∼2:1)
MPI-0454128 0.02 0.14 7.90 plakinidines A (1)a n dC( 3)( ∼2:1)
MPI-0454141 0.17 1.10 5.91 plakinidine B (2)
MPI-0453967 0.23 1.37 5.91 plakinidines A (1) ,B( 2), and C (3)( ∼1:1:8)
mitomycin C 0.005 0.4 292
a The fold change in the IC50 values of proﬁcient, BAC29, and deﬁcient V-C8 cell lines was reported as the selectivity index, SI.
b Ratio could not be
determined due to a poor baseline in the 1H spectrum.
Figure 1. Five samples (MPI-0454126, -0454127, -0454128,
-0454141, and -0453967) reduce the electrophoretic mobility of
negatively supercoiled DNA, indicative of DNA intercalation. MPI
compounds (including two unrelated samples, MPI-0454154 and
-00454713, as negative controls) were incubated with DNA at a
concentration of 33 µM prior to electrophoresis. Doxorubicin, a
known intercalator, was included at 50 µM as a positive control.
Relaxed circular and linear DNA markers were included on the
gel for reference.
1096 Journal of Natural Products, 2008, Vol. 71, No. 6 Notesthe source organism. Our methods also allowed identiﬁcation of
the plakinidines from a sponge that was previously reported to
produce cytotoxic compounds, but not the plakinidines. The
prevalence of the cytotoxic crellastatins
20 could easily mask the
presence of the minor plakinidines using traditional bioassay-guided
isolation. These studies indicate that our methodology can uncover
components that have been previously masked by major bioactive
compounds.
Overall, we were able to create a large MNP library consisting
of pure and semipure samples for drug discovery. Online mass
measurements expedited the identiﬁcation of known compounds,
and we anticipate that the MS data will facilitate the identiﬁcation
of novel chemotypes in conjunction with taxonomy of the producing
organism and database queries.
Experimental Section
General Experimental Procedures. All NMR data were obtained
at 600 MHz on a Varian INOVA equipped with a cryogenically cooled
1H channel. For gCOSY, gHMBC, and gHSQC experiments, stand-
ard vendor-supplied pulse sequences were used. Samples were dissolved
in 250 µL of DMSO-d6 (Cambridge Isotope Laboratories) and placed
in a 5 mm, DMSO-matched Shigemi tube. Spectra were referenced to
DMSO resonances (δH 2.49 ppm; δC 39.5 ppm). All solvents used for
HPLC were Optima LCMS grade (Fisher Scientiﬁc). All NMR
resonances matched those previously published for plakinidines A (1),
B( 2), and C (3) in DMSO-d6.
19
Biological Material. Sponge specimens were collected in Fiji near
Naukathuvu Island using scuba. Voucher specimens for the Plakortis
quasiamphiaster (88-5-110) and the Crella spinulata (88-5-92) are
housed at the University of Utah.
Extraction and Chromatography. All invertebrates were extracted
with MeOH. The MeOH extract (24 mL) was loaded onto HP20SS
(200 mg) and subsequently dried using a centrifugal evaporator. After
the sample was dried, the “loaded” HP20SS was transferred to a 2.5 ×
9 cm polypropylene column ﬁtted with a frit. Fifteen milliliters of each
solvent (100% H2O, 25% IPA/H2O, 50% IPA/H2O, 75% IPA/H2O, and
100% MeOH) were pushed through the sample using a 60 mL syringe
ﬁtted to the top of the column to generate ﬁve eluates (FW, F1, F2,
F3, F4, respectively). The solvents were removed from all samples using
a centrifugal evaporator. The 100% H2O fraction was not subjected to
LCMS fractionation since we were attempting to create a library
consisting of “drug-like” molecules, and it contained predominately
sea salt. Each of the remaining four HP20SS eluates were dissolved in
an appropriate volume of 3:1 MeOH/H2O (F1), MeOH (F2 and F3), or
ethanol (F4). Two milligrams of each HP20SS fraction was transferred
into polypropylene 96-well plates (Greiner, 330 µL) for direct use in
the LCMS autosampler and subsequently dried in a centrifugal
evaporator, while the remaining material was aliquoted into a deep 96-
well plate (Greiner, 2 mL) for storage. Two hundred microliters of
DMSO was added to the LCMS autosampler plate and shaken for 1 h
to dissolve the sample.
LCMS Fractionation. The 96-well plate containing the dissolved
HP20SS fractions was placed in the autosampler rack of a Waters 2795
HT HPLC. A sample experiment report can be found in the Supporting
Information, which describes all parameters for HPLC, MS, and
FractionLynx. MassLynx 4.1 was used to control the 2795 HPLC and
the Micromass Q-tof Micro. The only parameter changed for each
HP20SS fraction was the curve applied to the gradient. For F1, a #7
curved gradient was used to achieve better separation of polar
metabolites, while a #5 curved gradient was used to achieve better
separation of nonpolar metabolites. For F2 and F3, a linear gradient
(#6) was used. HPLC separations were performed ona3m m× 100
mm Phenomenex Onyx C18 column equipped with a guard column at
a ﬂow rate of 1.5 mL min-1. Typically, a back pressure of ∼1500 psi
was observed at 10% CH3CN/H2O.
The HPLC efﬂuent was split after the PDA using an adjustable
splitter (Upchurch) that directed 30 µL min-1 to the Q-tof Micro.
Collection was directed to each polypropylene deep-well plate (Greiner,
2 mL) in the fraction collector in an identical pattern to that required
for screening, so that each well was appropriately mapped on the
chromatogram by FractionLynx. In our case, columns 1 and 12 were
empty.
The Waters fraction collector III was controlled by FractionLynx,
and the details of collection are in the Supporting Information.
Collection plates were dried in a centrifugal concentrator. The contents
of each well were dissolved in 500 µL of MeOH. Two daughter plates
were generated by transferring 250 µL to polypropylene shallow-well
96-well plates (Greiner, 330 µL). One plate was stored dry at -80 °C
for NMR analysis, while the other plate was resolubilized with 100
µL of DMSO to makea1m Mscreening plate. The concentration was
based on an average molecular mass of 500 Da and an estimate that
each well contains 50 µg.
For accurate mass measurements, leucine enkephalin was used as a
reference mass [M + H]+ m/z 556.2771. This mass does not account
for the loss of an electron, but is consistent with the molecular formula
generator in MassLynx 4.1. All data were centroided, and the lock mass
correction was applied during acquisition in order to reduce the ﬁle
size. Accurate mass measurements were obtained directly from the MS
data acquired during automated fractionation. Each was averaged over
an area where the signal intensity was less than 0.1 ion per pusher
pulse to ensure that the detector was not saturated.
Plakinidine A (1): HRESIMS [M + H]+ m/z 303.1243, calcd
303.1246 for C18H15N4O( ∆ -1.0 ppm).
Plakinidine B (2): HRESIMS [M + H]+ m/z 317.1395, calcd
317.1410 for C19H17N4O( ∆ -2.2 ppm).
Plakinidine C (3): HRESIMS [M + H]+ m/z 301.1075, calcd
301.1089 for C18H13N4O( ∆ -4.6 ppm).
Cell-Based Assay for Differential Cytotoxicity. The V-C8 mutant
cell line derived from the Chinese hamster V79 cells and the BRCA2-
complemented BAC29 cell line have been described previously.
15 Cells
were routinely cultured in DMEM medium (Invitrogen) supplemented
with 10% fetal bovine serum (Hyclone), 1 mM HEPES, 1 mM pyruvate,
1 mM glutamate, and nonessential amino acids. The BAC29 cells were
also maintained in medium containing G418. Cells were maintained at
37 °C in a humidiﬁed 5% CO2 atmosphere. In a preliminary experiment
the optimal seeding density for each cell line and compound concentra-
tion range was determined. For the selectivity screen, V-C8 cells were
seeded at 4000 cells/well and BAC29 cells at 3500 cells/well in 96-
well clear-bottom plates (Greiner). Both cell lines were treated with
compound, in triplicate, and allowed to grow for 3 days. After 3 days
of compound exposure, the WST1 cell viability assay was performed
and the absorbance read at A490. Dose-response curves were generated
with the help of Prism software by plotting percentage of A490
reduction in compound-treated relative to vehicle- or DMSO-treated
cells.
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